{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:30:57Z","timestamp":1789943457758,"version":"4.0.1"},"reference-count":139,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.urolonc.2021.05.015","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T03:40:44Z","timestamp":1624333244000},"page":"642-663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Non-muscle-invasive bladder cancer: An overview of potential new treatment options"],"prefix":"10.1016","volume":"39","author":[{"given":"Neal D.","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou Redorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregoire","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossano","family":"Cesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"Hariharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Rodr\u00edguez Faba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.05.015_bib0001","unstructured":"World Health Organization. Population Fact Sheets: World, Available at: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/900-world-fact-sheets.pdf; 2018 [accessed 27 October 2020]."},{"key":"10.1016\/j.urolonc.2021.05.015_bib0002","unstructured":"European Commission. Estimates of cancer incidence and mortality in 2020, for all cancer sites, Available at: https:\/\/ecis.jrc.ec.europa.eu\/index.php; 2020 [accessed 5 November 2020]."},{"key":"10.1016\/j.urolonc.2021.05.015_bib0003","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0004","first-page":"507","article-title":"Bladder cancer: diagnosis and treatment","volume":"96","author":"DeGeorge","year":"2017","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0006","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0007","unstructured":"National Institute for Health and Care Excellence. Managing non-muscle-invasive bladder cancer, Available at:https:\/\/pathways.nice.org.uk\/pathways\/bladder-cancer#path=view%3A\/pathways\/bladder-cancer\/managing-non-muscle-invasive-bladder-cancer.xml&content=view-index; 2020 [accessed 27 October 2020]."},{"key":"10.1016\/j.urolonc.2021.05.015_bib0008","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0009","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0011","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0012","article-title":"Recurrence rate and cost consequence of the shortage of bacillus Calmette-Gu\u00e9rin Connaught strain for bladder cancer patients","volume":"S2405-4569","author":"Ourfali","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S202006","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) therapy for bladder cancer: an update","volume":"9","author":"Guallar-Garrido","year":"2020","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0014","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0015","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Keytruda (pembrolizumab), Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125514s066lbl.pdf; 2020 [accessed 27 October 2020]."},{"key":"10.1016\/j.urolonc.2021.05.015_bib0016","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Valstar (valrubicin), Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020892s019lbl.pdf; 2016 [accessed 3 November 2020]."},{"key":"10.1016\/j.urolonc.2021.05.015_bib0017","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0018","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-017-0271-0","article-title":"Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma","volume":"5","author":"Kamat","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0019","unstructured":"Babjuk M, Burger M, Comperat EM, Palou Redorta J, van Rhijn BWG, Roupret M, et al. Statement concerning the shortage of BCG vaccine from the EAU Guidelines Panel on Non-muscle-invasive Bladder Cancer, Available at:https:\/\/uroweb.org\/wp-content\/uploads\/Updated-statement-concerning-the-shortage-of-BCG-vaccine-NMIBC-Panel-2018.pdf; 2020 [accessed 27 October 2020]."},{"key":"10.1016\/j.urolonc.2021.05.015_bib0020","unstructured":"American Urological Association. Important message about the BCG shortage, Available at: https:\/\/www.auanet.org\/\/about-us\/bcg-shortage-info; 2020 [accessed 27 October 2020]."},{"key":"10.1016\/j.urolonc.2021.05.015_bib0021","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MOU.0000000000000086","article-title":"Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection","volume":"24","author":"Seisen","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0022","article-title":"PD12-10\u2003Management of variant histology in non-muscle invasive bladder cancer","volume":"203","author":"Prado","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0023","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/MOU.0000000000000089","article-title":"Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer","volume":"24","author":"Porten","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0024","doi-asserted-by":"crossref","first-page":"34","DOI":"10.21037\/tau.2019.01.09","article-title":"Histological variants in non-muscle invasive bladder cancer","volume":"8","author":"Baumeister","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0025","first-page":"1","article-title":"Non-muscle invasive bladder cancer with variant histology: biological features and clinical implications","author":"Sanguedolce","year":"2021","journal-title":"Oncology"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0026","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrurol.2017.125","article-title":"Characteristics and clinical significance of histological variants of bladder cancer","volume":"14","author":"Moschini","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0027","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11934-019-0949-6","article-title":"Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes","volume":"20","author":"Aron","year":"2019","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0028","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.6004\/jnccn.2017.7027","article-title":"Clinical Significance of Histologic Variants of Bladder Cancer","volume":"15","author":"Warrick","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0029","doi-asserted-by":"crossref","DOI":"10.21037\/amj.2020.02.02","article-title":"The impact of histological variants on bladder cancer outcomes","volume":"5","author":"Processali","year":"2020","journal-title":"AME Medical Journal"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pathol.2020.09.004","article-title":"Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes","volume":"53","author":"Takahara","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0031","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0032","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrurol.2013.194","article-title":"BCG immunotherapy for bladder cancer\u2013the effects of substrain differences","volume":"10","author":"Gan","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0033","doi-asserted-by":"crossref","first-page":"484.e19","DOI":"10.1016\/j.urolonc.2016.05.033","article-title":"The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0034","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0035","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus Calmette-Gu\u00e9rin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0036","article-title":"Comparative effectiveness of intravesical BCG-Tice and BCG-Moreau in patients with non-muscle-invasive bladder cancer","volume":"18","author":"D'Andrea","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0037","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000492722","article-title":"Are there differences in toxicity and efficacy between various bacillus Calmette-Guerin strains in bladder cancer patients? Analysis of 844 patients","volume":"101","author":"Krajewski","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0038","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2018.08.015","article-title":"Background and update for S1602 \"a phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-na\u00efve high-grade non-muscle-invasive bladder cancer","volume":"4","author":"Svatek","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0039","unstructured":"US Food and Drug Administration. Bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry, Available at:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and; 2018 [accessed 27 October 2020]."},{"key":"10.1016\/j.urolonc.2021.05.015_bib0040","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0041","first-page":"145","article-title":"Intravesical therapy for non-muscle invasive bladder cancer-current and future options in the age of bacillus Calmette-Guerin shortage","volume":"21","author":"Golla","year":"2019","journal-title":"Rev Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0042","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/iju.IJU_296_17","article-title":"New therapies in nonmuscle invasive bladder cancer treatment","volume":"34","author":"Rayn","year":"2018","journal-title":"Indian J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0043","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 blockade in cancer immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0044","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.urolonc.2017.12.020","article-title":"Role of immunotherapy in bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer","volume":"36","author":"Mukherjee","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0045","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/OTT.S165840","article-title":"Bacillus Calmette-Gu\u00e9rin and anti-PD-L1 combination therapy boosts immune response against bladder cancer","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0046","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1200\/JCO.2019.37.15_suppl.4550","article-title":"PD-L1\/PD-1 expression as a predictor of response to BCG in patients with high-risk non\u2013muscle invasive bladder cancer","volume":"37","author":"Roumiguie","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0047","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1245\/s10434-018-6498-2","article-title":"Clinical role of programmed cell death-1 expression in patients with non-muscle-invasive bladder cancer recurring after initial bacillus Calmette-Gu\u00e9rin therapy","volume":"25","author":"Fukumoto","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0048","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0049","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1200\/JCO.2019.37.15_suppl.4561","article-title":"Soon-Shiong P. Preliminary phase 2 clinical results of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients","volume":"37","author":"Chamie","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0050","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/14737140.2020.1822743","article-title":"Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer","volume":"20","author":"Moussa","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0051","doi-asserted-by":"crossref","first-page":"e96705","DOI":"10.1371\/journal.pone.0096705","article-title":"Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion","volume":"9","author":"Gomes-Giacoia","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0052","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/JCO.2018.36.6_suppl.510","article-title":"Phase Ib trial of ALT-803, an IL-15 superagonist, plus BCG for the treatment of BCG-na\u00efve patients with non-muscle-invasive bladder cancer","volume":"36","author":"Rosser","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0053","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-9966-28-3","article-title":"Effect of sirolimus on urinary bladder cancer T24 cell line","volume":"28","author":"Pinto-Leite","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0054","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/1940-6207.CAPR-09-0169","article-title":"Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer","volume":"2","author":"Seager","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0055","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.humpath.2012.11.026","article-title":"Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non\u2013muscle invasive bladder cancer","volume":"44","author":"Fahmy","year":"2013","journal-title":"Human Pathol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2021.05.015_bib0056","doi-asserted-by":"crossref","first-page":"e17039","DOI":"10.1200\/JCO.2020.38.15_suppl.e17039","article-title":"Phase Ib study: APL-1202 (APL) in combination with bacillus Calmette-Guerin (BCG) in recurrent non-muscle invasive bladder cancer (NMIBC)","volume":"38","author":"Sfakianos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7_suppl","key":"10.1016\/j.urolonc.2021.05.015_bib0057","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/jco.2015.33.7_suppl.293","article-title":"Phase II clinical trial of intravesical bacillus Calmette-Guerin (BCG) followed by sunitinib for the treatment of high-risk nonmuscle-invasive bladder cancer (NMIBC)","volume":"33","author":"Helfand","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0058","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.juro.2013.12.011","article-title":"DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer","volume":"191","author":"Gofrit","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0059","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1200\/JCO.2018.36.6_suppl.499","article-title":"Phase II trial of BC-819 intravesical gene therapy in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC)","volume":"36","author":"Halachmi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0060","doi-asserted-by":"crossref","first-page":"e16016","DOI":"10.1200\/JCO.2016.34.15_suppl.e16016","article-title":"Phase I\/II canon study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21","volume":"34","author":"Pandha","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0061","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","article-title":"Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer","volume":"25","author":"Annels","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2018.02.001","article-title":"Oncolytic immunotherapy for bladder cancer using Coxsackie A21 virus","volume":"9","author":"Annels","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0063","doi-asserted-by":"crossref","first-page":"viii732","DOI":"10.1093\/annonc\/mdy424.050","article-title":"Phase Ib KEYNOTE-200: a study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients","volume":"29","author":"Rudin","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0064","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/2326-6066.CIR-18-0671","article-title":"Intravesical Ty21a vaccine promotes dendritic cells and T cell-mediated tumor regression in the MB49 bladder cancer model","volume":"7","author":"Domingos-Pereira","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0065","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1265720","article-title":"Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer","volume":"6","author":"Domingos-Pereira","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0066","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.21873\/anticanres.11218","article-title":"A single intravesical instillation of VAX014 inhibits orthotopic superficial bladder tumor implantation to increase survival","volume":"36","author":"Hancock","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0067","doi-asserted-by":"crossref","first-page":"e12740","DOI":"10.1097\/MD.0000000000012740","volume":"97","author":"Naya","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0068","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fonc.2017.00260","article-title":"Intravesical gemcitabine versus intravesical bacillus Calmette-Gu\u00e9rin for the treatment of non-muscle invasive bladder cancer: an evaluation of efficacy and toxicity","volume":"7","author":"Prasanna","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0069","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2019.37.7_suppl.469","article-title":"Sequential intravesical gemcitabine and docetaxel in the treatment of BCG-naive patients with non-muscle invasive bladder cancer","volume":"37","author":"Thomas","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0070","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0071","doi-asserted-by":"crossref","first-page":"40.e17","DOI":"10.1016\/j.urolonc.2019.07.022","article-title":"An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine\/docetaxel for nonmuscle-invasive bladder cancer","volume":"38","author":"Daniels","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0072","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0022-5347(01)62377-2","article-title":"Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer","volume":"160","author":"Witjes","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0073","doi-asserted-by":"crossref","first-page":"TPS602","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS602","article-title":"Adding mitomycin to bacillus Calmette-Gu\u00e9rin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301)","volume":"38","author":"Liow","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0074","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028287","article-title":"Protocol for phase I study of pembrolizumab in combination with bacillus Calmette-Gu\u00e9rin for patients with high-risk non-muscle invasive bladder cancer","volume":"9","author":"Jamil","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0075","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0076","doi-asserted-by":"crossref","first-page":"39.e1","DOI":"10.1016\/j.urolonc.2016.09.006","article-title":"A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer","volume":"35","author":"Donin","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0077","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919890285","article-title":"Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors","volume":"11","author":"Casadei","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0078","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/JCO.2020.38.6_suppl.510","article-title":"Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer","volume":"38","author":"Cha","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0079","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1186\/s12885-019-6346-1","article-title":"Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer","volume":"19","author":"Molenaar","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0080","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1158\/1078-0432.CCR-14-1781","article-title":"Sequential intravesical mitomycin plus bacillus Calmette\u2013Gu\u00e9rin for non\u2013muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial","volume":"21","author":"Svatek","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0081","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1200\/JCO.2020.38.15_suppl.5041","article-title":"Pembrolizumab (pembro) for the treatment of patients with bacillus Calmette-Gu\u00e9rin (BCG) unresponsive, high-risk (HR) non\u2013muscle-invasive bladder cancer (NMIBC): over two years follow-up of KEYNOTE-057","volume":"38","author":"Balar","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0082","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1200\/JCO.2020.38.15_suppl.5022","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)","volume":"38","author":"Black","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0083","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0084","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2019.37.7_suppl.358","article-title":"BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC)","volume":"37","author":"Luke","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0085","doi-asserted-by":"crossref","first-page":"e15509","DOI":"10.1200\/jco.2015.33.15_suppl.e15509","article-title":"Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer (NMIBC)","volume":"33","author":"Sonpavde","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0086","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The cytosolic DNA-sensing cGAS\u2013STING pathway in cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0087","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.molmed.2019.02.007","article-title":"Pharmacological modulation of the STING pathway for cancer immunotherapy","volume":"25","author":"Berger","year":"2019","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0088","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.7150\/thno.37574","article-title":"STING activation in cancer immunotherapy","volume":"9","author":"Su","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0089","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","article-title":"STING: a master regulator in the cancer-immunity cycle","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0090","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1158\/1538-7445.AM2020-592","article-title":"Abstract 592: Demonstration of E7766, a novel STING agonist, as a potent immunotherapy in BCG-insensitive non-muscle invasive bladder cancer models via intravesical administration","volume":"80","author":"Huang","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0091","article-title":"VISTA, phase 3 trial of vicinium, an EpCAM-targeted pseudomonas exotoxin, in BCG-unresponsive non-muscle invasive bladder cancer","author":"Dickstein","year":"2018","journal-title":"Global Congress on Bladder Cancer"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0092","article-title":"PD03-02\u2003Phase 3 results of vicinium in BCG-unresponsive non-muscle invasive bladder cancer","volume":"203","author":"Shore","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0093","unstructured":"Sesen Bio. Sesen Bio reports positive, preliminary data update from phase 3 VISTA trial for high-risk non-muscle invasive bladder cancer [press release], Available at: https:\/\/ir.sesenbio.com\/news-releases\/news-release-details\/sesen-bio-reports-positive-preliminary-data-update-phase-3-vista; 2019 [accessed 27 October 2020]."},{"key":"10.1016\/j.urolonc.2021.05.015_bib0094","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/JCO.2020.38.6_suppl.442","article-title":"SUO Clinical Trials Consortium. Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): results from a phase III trial","volume":"38","author":"Boorjian","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0095","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2013armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0096","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0097","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0098","first-page":"e617","article-title":"CG0070, an oncolytic adenovirus, for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC): 18 month follow-up from a multicenter phase II trial","volume":"201","author":"Packiam","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0099","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fonc.2019.00121","article-title":"Combination of intravesical bacille Calmette-Gu\u00e9rin and chemotherapy vs. bacille Calmette-Gu\u00e9rin alone in non-muscle invasive bladder cancer: a meta-analysis","volume":"9","author":"Huang","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus Calmette-Gu\u00e9rin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"DeCastro","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0101","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.urology.2017.01.018","article-title":"Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous bacillus Calmette-Gu\u00e9rin therapy","volume":"103","author":"Robins","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0102","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ijc.32556","article-title":"Proteome-based classification of nonmuscle invasive bladder cancer","volume":"146","author":"Stroggilos","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0103","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0104","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1200\/JCO.2021.39.6_suppl.483","article-title":"Transcriptome analysis of low-risk and high-risk non-muscular invasive bladder cancer patients to reveal disease progression related genes","volume":"39","author":"Fu","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ajpath.2019.10.004","article-title":"Next-generation sequencing reveals potential predictive biomarkers and targets of therapy for urothelial carcinoma in situ of the urinary bladder","volume":"190","author":"Garczyk","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0106","article-title":"An integrated multi-omics analysis identifies clinically relevant molecular subtypes of non-muscle-invasive bladder cancer","author":"Lindskrog","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0107","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41585-018-0092-z","article-title":"Intravesical device-assisted therapies for non-muscle-invasive bladder cancer","volume":"15","author":"Tan","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0108","doi-asserted-by":"crossref","first-page":"94","DOI":"10.21037\/tau.2018.09.09","article-title":"Device-assisted intravesical therapy for non-muscle invasive bladder cancer","volume":"8","author":"Hendricksen","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0109","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000502663","article-title":"Intravesical treatment with electro-mediated administration of mytomicin C as prophylaxis for intermediate and high-risk nonmuscle-invasive bladder cancer: a retrospective multicenter study","volume":"103","author":"Carando","year":"2019","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0110","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.eururo.2006.08.025","article-title":"New frontiers in intravesical therapies and drug delivery","volume":"50","author":"Giannantoni","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0111","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of mitomycin C as first-line salvage therapy in high risk \"BCG failure\" non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0112","article-title":"Intravesical electromotive drug administration for non-muscle invasive bladder cancer","volume":"9","author":"Jung","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0113","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.06.031","article-title":"Sequential administration of bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure","volume":"38","author":"Juvet","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0114","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0115","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/02656736.2019.1646929","article-title":"Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate- and high-risk nonmuscle-invasive bladder cancer: a single-institution nonrandomized concurrent controlled trial","volume":"36","author":"Zhou","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0116","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/02656736.2016.1142618","article-title":"Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate\u2013high-risk non-muscle-invasive bladder cancer","volume":"32","author":"Sousa","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0117","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","article-title":"Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients","volume":"4","author":"de Jong","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0118","first-page":"e1119","article-title":"Chemohyperthermia with mitomycin C and combat system a new alternative to BCB in high risk non muscle invasive bladder cancer?","volume":"199","author":"Bello","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0119","first-page":"e229","article-title":"Oncological outcomes of BCG unresponsive non-muscle invasive bladder cancer patients treated with postoperative chemohyperthermia: a multicentre European retrospective analysis","volume":"201","author":"Tan","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000435788","article-title":"Predictive factors for time to progression after hyperthermic mitomycin C treatment for high-risk non-muscle invasive urothelial carcinoma of the bladder: an observational cohort study of 97 patients","volume":"96","author":"Sooriakumaran","year":"2016","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0121","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2217\/fon.12.90","article-title":"10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer","volume":"8","author":"Moskovitz","year":"2012","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0122","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","article-title":"Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party","volume":"27","author":"Witjes","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0123","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0124","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.juro.2014.03.101","article-title":"Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer","volume":"192","author":"Arends","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0125","first-page":"e1115","article-title":"LBA02-03 Can TURBT be avoided? Primary chemoablation with a reverse thermal gel containing mitomycin (UGN-102) in patients with low grade intermediate risk non-muscle invasive bladder cancer","volume":"203","author":"Huang","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0126","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.euf.2019.09.006","article-title":"Overview of Taris GemRIS, a novel drug delivery system for bladder cancer","volume":"6","author":"Grimberg","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0127","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/S0022-5347(05)66239-8","article-title":"Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer","volume":"165","author":"Waidelich","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0128","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1089\/089277903322518644","article-title":"Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium","volume":"17","author":"Manyak","year":"2003","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/clm.1998.16.61","article-title":"Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience","volume":"16","author":"Nseyo","year":"1998","journal-title":"J Clin Laser Med Surg"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0130","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.juro.2013.04.077","article-title":"Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Gu\u00e9rin immunotherapy","volume":"190","author":"Lee","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0131","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0090-4295(02)02123-4","article-title":"Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study","volume":"61","author":"Berger","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0132","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.juro.2011.11.080","article-title":"Antitumor effects ofcis-Urocanic acid on experimental urothelial cell carcinoma of the bladder","volume":"187","author":"Arentsen","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0133","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41585-019-0184-4","article-title":"Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018","volume":"16","author":"Lotan","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0134","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0135","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.juro.2017.11.096","article-title":"Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: a phase III, comparative, multicenter study","volume":"199","author":"Daneshmand","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0136","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1089\/end.2015.0336","article-title":"Thulium laser endoscopic en bloc enucleation of nonmuscle-invasive bladder cancer","volume":"29","author":"Migliari","year":"2015","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0137","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2016.01.004","article-title":"\u201cEn bloc\u201d resection of nonmuscle invasive bladder cancer: a prospective single-center study","volume":"90","author":"Hurle","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0138","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00345-015-1568-6","article-title":"En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor","volume":"33","author":"Kramer","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2021.05.015_bib0139","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.euf.2016.12.004","article-title":"Current evidence of transurethral en-bloc resection of nonmuscle invasive bladder cancer","volume":"3","author":"Kramer","year":"2017","journal-title":"Eur Urol Focus"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921002210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921002210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:24:13Z","timestamp":1761042253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921002210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":139,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1078143921002210"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.015","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-muscle-invasive bladder cancer: An overview of potential new treatment options","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Pfizer Inc. and the Author(s). Elsevier Inc.","name":"copyright","label":"Copyright"}]}}